الفهرس 
Etiology, Risk Factors, and PreventionOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
dvanced gastric cancer remains one of the leading causes of death by neoplasia worldwide (1). There is no standard treatment has been accepted for patients with advanced gastric cancer. Regimens containing 5-FU and cisplatin have been the most commonly used chemotherapy choices with reported response rates of 25–32 % and a median overall survival of 8.6–9.3 months 10,116). Docetaxel is an active agent for advanced gastric cancer. Docetaxel can incorporate many chemotherapy agents including cisplatin, oxaliplatin, 5-FU capecitabine and S-1In the V325 phase III trial, demonstrated an incremental benefit of adding docetaxel to the reference CF regimen as first-line therapy in patients with advanced gastric cancer. Myelosuppression, the most significant side effect, can be minimized when docetaxel is administered on a weekly schedule Due to these observations, we evaluated biweekly scheduling of DC combined with weekly fluorouracil–leucovorin. The weekly administration of DCF appears to be well tolerated, with limited hematologic toxicities.